查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1986600

全球家用性行為感染傳染感染檢測市場：市場規模、佔有率和趨勢分析（按感染疾病、檢體類型、樣本類型、分銷管道和地區分類），細分市場預測（2026-2033 年）

At-Home STI Testing Market Size, Share & Trends Analysis Report By Infection (HIV, CT), By Test Type (Molecular/NAAT-based Kits, Multiplex Panel Testing), By Sample Type, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

家庭性行為感染感染檢測市場概述

2025 年全球家庭性性行為感染檢測市場規模估計為 29.8 億美元，預計到 2033 年將達到 58.6 億美元，2026 年至 2033 年的複合年成長率為 8.85%。

披衣菌感染、淋病、梅毒和愛滋病等性行為感染（STI）的感染率不斷上升，加上人們對私密便捷的檢測解決方案的認知和需求不斷提高，正在顯著推動市場成長。

世界衛生組織（世衛組織）的數據顯示，全球每天性行為感染）病例超過100萬例；美國疾病管制與預防中心（CDC）報告稱，美國每年確診的披衣菌感染、淋病和梅毒病例超過240萬例。性傳染感染若未得到診斷及治療，可能導致嚴重的生殖系統健康併發症、不孕不孕、不良妊娠結局以及愛滋病毒感染風險增加，因此，亟需便捷的篩檢方案，例如居家性行為感染檢測。

越來越多的非處方家用性行為感染(STI) 診斷解決方案獲得監管機構核准，顯著加速了市場滲透。 2025 年 3 月，美國食品藥物管理局(FDA) 批准了 Visby Medical 公司的「女性性健康核准」上市，這是首款可在約 30 分鐘內檢測出披衣菌感染、淋病和滴蟲病的完整家用診斷試劑盒。這項突破性進展標誌著以消費者主導的性行為感染診斷領域的一個重要轉折點，它無需就醫即可快速檢測，並擴大了精準家用檢測的覆蓋範圍。

快速自我檢測技術的進步進一步提升了診斷的便利性和速度。 2025年10月，FDA核准了bioLytical Laboratories公司的“INSTI HIV自檢試劑盒”，這是一種指尖採血檢測，約一分鐘即可出結果，顯著降低了檢測門檻，使個人能夠立即了解自身感染狀況。此外，OraQuick等快速口腔液檢測的持續普及，透過無痛便捷的自我檢測方式，推動了HIV篩檢的推廣。這些創新提高了檢測的便利性和私密性，進一步鼓勵了消費者使用。

分子診斷和多種性傳染感染檢測技術的創新正在提升居家診斷的臨床可靠性和適用性。新型居家分子檢測能夠從單一檢體同時檢測多種感染疾病，進而提高篩檢效率和病患依從性。例如，能夠從單一檢體中檢測衣原體、淋病、黴漿菌和披衣菌感染支原體等多種性傳播感染疾病的檢測方案，正透過遠距遠端醫療支援的診療​​路徑得到應用，從而改善全面的性健康篩檢和後續護理。多種檢測的普及提高了診斷準確性，同時也增強了居家篩檢的提案。

公共衛生舉措和數位健康推廣計畫也正在擴大高風險族群和弱勢族群居家性行為感染檢測的覆蓋範圍。例如，由美國疾病管制與預防中心支持的「攜手帶我回家」（Together TakeMeHome）舉措已在美國各地分發了數十萬份免費的愛滋病毒居家自檢檢測套組，有助於早期發現感染者，並擴大了首次接受檢測人群的覆蓋範圍。同時，各國政府和醫療衛生系統也日益認知到居家檢測的重要性，將其視為提高篩檢率、減少歧視障礙和支持早期治療的關鍵策略。這些努力正在加強居家性行為感染檢測在預防醫學和疾病控制策略中的作用。

然而，診斷準確性、檢體採集不當以及用戶誤判等問題會影響檢測的可靠性，預計這將抑制市場成長，尤其是對於自行操作的快速檢測而言。此外，保險報銷和自付費用方面的限制可能會限制價格敏感型市場的普及，尤其是在公共衛生計畫主要支持醫療機構篩檢的地區。關於數位化結果報告和與遠端醫療整合的隱私問題也持續影響消費者的信心。此外，各國法規結構和品質標準的差異也對旨在拓展全球市場的製造商構成了障礙。

目錄

第1章：分析方法和範圍

第2章執行摘要

第3章：性行為感染檢測市場：影響因素、趨勢與範圍

  • 市場歷史及展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
  • 居家性行為感染檢測市場分析工具
    • 產業分析：波特五力分析
    • PESTEL 分析

第4章：性行為感染傳染病檢測市場：依感染疾病的估價與趨勢分析

  • 性行為感染檢測市場：感染疾病類型分類的波動分析
  • 家庭性行為感染檢測市場：依感染疾病。
  • 市場規模、預測與趨勢分析（2021-2033）：以下項目
  • HIV
  • 披衣菌感染（CT）
  • 淋病（NG）
  • 梅毒
  • 滴蟲病
  • HPV
  • 乙型/丙型肝炎
  • 其他

第5章：居家性行為感染檢測市場：依檢測類型分類的估算與趨勢分析

  • 性行為感染檢測市場：感染疾病類型分類的波動分析
  • 家庭性行為感染檢測市場：依感染疾病。
  • 市場規模、預測與趨勢分析（2021-2033）：以下項目
  • 快速側向流動免疫檢測
  • 分子測試/基於 NAAT 的試劑盒
  • 多組面板測試
  • 其他

第6章：居家性行為感染檢測市場：依檢體類型分類的估算與趨勢分析

  • 性行為感染檢測市場：依檢體類型分類的波動分析
  • 居家性行為感染檢測市場：依檢體類型分類的展望
  • 市場規模、預測與趨勢分析（2021-2033）：以下項目
  • 血
  • 尿
  • 口腔液/唾液
  • 陰道拭子
  • 其他

第7章：居家性行為感染檢測市場：按分銷管道分類的估算與趨勢分析

  • 性行為感染檢測市場：按分銷管道分類的波動分析
  • 居家性行為感染檢測市場：按分銷管道分類的展望
  • 市場規模、預測與趨勢分析（2021-2033）：以下項目
  • 線上藥房，D2C平台
  • 零售藥房
  • 公共衛生分發計劃
  • 其他

第8章：性行為感染檢測市場：區域估算與趨勢分析

  • 區域儀錶板
  • 市場規模、預測與趨勢分析（2021-2033）：
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭情勢

  • 參與企業的分類
  • 近期趨勢及影響分析：依主要市場參與企業
  • 企業市場占有率分析（2025 年）
  • 主要企業公司簡介
    • OraSure Technologies Inc.
    • Abbott
    • bioLytical Laboratories Inc.
    • Chembio Diagnostics, Inc.
    • BD（Becton Dickinson）
    • LetsGetChecked
    • Everlywell
    • NURX Inc.
    • Hologic, Inc.
Product Code: GVR-4-68040-863-3

At-Home STI Testing Market Summary

The global at-home STI testing market size was estimated at USD 2.98 billion in 2025 and is projected to reach USD 5.86 billion by 2033, growing at a CAGR of 8.85% from 2026 to 2033. The rising prevalence of sexually transmitted infections (STIs) such as chlamydia, gonorrhea, syphilis, and HIV, along with increasing awareness and demand for private, convenient testing solutions, is significantly driving market growth.

According to the World Health Organization, more than 1 million STIs are acquired every day worldwide, while the Centers for Disease Control and Prevention reports over 2.4 million cases of chlamydia, gonorrhea, and syphilis annually in the U.S. If left undiagnosed and untreated, STIs can lead to severe reproductive health complications, infertility, adverse pregnancy outcomes, and increased HIV transmission risk, underscoring the critical need for accessible screening solutions such as at-home STI testing.

The increasing number of regulatory clearances for fully at-home and over-the-counter STI diagnostic solutions is significantly accelerating market adoption. In March 2025, the U.S. Food and Drug Administration granted marketing authorization to Visby Medical's Women's Sexual Health Test, the first fully at-home diagnostic capable of detecting chlamydia, gonorrhea, and trichomoniasis with results in approximately 30 minutes. This milestone marks a major shift toward consumer-operated STI diagnostics, enabling rapid detection without laboratory visits and expanding access to accurate home-based testing.

Advancements in rapid self-testing technologies are further improving accessibility and speed of diagnosis. In October 2025, the FDA approved the INSTI HIV Self-Test from bioLytical Laboratories, a finger-stick blood test delivering results in about one minute, significantly reducing testing barriers and enabling immediate status awareness. In addition, continued availability of oral-fluid rapid tests such as OraQuick supports broader HIV screening uptake through painless, user-friendly self-testing options. These innovations enhance convenience and privacy, further driving consumer adoption.

Technological innovation in molecular and multiplex STI testing is expanding the clinical reliability and scope of home diagnostics. New home-collected molecular tests enable simultaneous detection of multiple infections from a single specimen, improving screening efficiency and patient compliance. For example, multiplex STI testing solutions capable of detecting infections such as chlamydia, gonorrhea, trichomoniasis, and Mycoplasma genitalium from one sample are being deployed through telehealth-enabled care pathways, improving comprehensive sexual health screening and follow-up care. The expansion of multiplex testing is increasing diagnostic accuracy while enhancing the value proposition of at-home screening.

Public health initiatives and digital health distribution programs are also expanding access to home STI testing among high-risk and underserved populations. Programs such as the CDC-supported Together TakeMeHome initiative have distributed hundreds of thousands of free at-home HIV self-tests across the U.S., improving early detection and reaching first-time testers. In parallel, governments and healthcare systems increasingly recognize home testing as a critical strategy to improve screening rates, reduce stigma barriers, and support early treatment. These initiatives are strengthening the role of at-home STI testing in preventive healthcare and disease control strategies.

However, factors such as concerns regarding diagnostic accuracy, improper sample collection, and user interpretation errors can affect test reliability, particularly for self-administered rapid tests, which are anticipated to restrain market growth. Reimbursement limitations and out-of-pocket costs may restrict adoption in price-sensitive markets, especially where public health programs primarily support clinic-based screening. Privacy concerns related to digital result reporting and telehealth integration also continue to influence consumer trust. Furthermore, variability in regulatory frameworks and quality standards across countries creates barriers for manufacturers seeking global expansion.

Global At-home STI Testing Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global at-home STI testing market report based on infection, test type, sample type, distribution channel, and region:

  • Infection Outlook (Revenue, USD Million, 2021 - 2033)
  • HIV
  • Chlamydia (CT)
  • Gonorrhea (NG)
  • Syphilis
  • Trichomoniasis
  • HPV
  • Hepatitis B & C
  • Others
  • Test Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Rapid Lateral Flow Immunoassays
  • Molecular / NAAT-based Kits
  • Multiplex Panel Testing
  • Others
  • Sample Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Blood
  • Urine
  • Oral Fluid/Saliva
  • Vaginal Swab
  • Others
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Online Pharmacies & D2C Platforms
  • Retail Pharmacies
  • Public Health Distribution Programs
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Norway
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Infection
    • 1.2.2. Test Type
    • 1.2.3. Sample Type
    • 1.2.4. Distribution Channel
    • 1.2.5. Regional Scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. At-home STI Testing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising global prevalence of sexually transmitted infections (STIs)
      • 3.2.1.2. Increasing adoption of telehealth and digital sexual health services
      • 3.2.1.3. Growing demand for private, convenient, and stigma-free testing solutions
      • 3.2.1.4. Regulatory approvals and technological advancements in self-testing diagnostics
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Concerns regarding test accuracy and improper sample collection
      • 3.2.2.2. Limited reimbursement coverage and affordability constraints in emerging markets
  • 3.3. At-home STI Testing Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. At-home STI Testing Market: Infection Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. At-home STI Testing Market: Infection Movement Analysis
  • 4.3. At-home STI Testing Market by Infection Outlook (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2021 - 2033 for the following
  • 4.5. HIV
    • 4.5.1. HIV Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Chlamydia (CT)
    • 4.6.1. Chlamydia (CT) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Gonorrhea (NG)
    • 4.7.1. Gonorrhea (NG) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.8. Syphilis
    • 4.8.1. Syphilis Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.9. Trichomoniasis
    • 4.9.1. Trichomoniasis Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.10. HPV
    • 4.10.1. HPV Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.11. Hepatitis B & C
    • 4.11.1. Hepatitis B & C Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.12. Others
    • 4.12.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. At-home STI Testing Market: Test Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. At-home STI Testing Market: Test Type Movement Analysis
  • 5.3. At-home STI Testing Market by Test Type Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 - 2033 for the following
  • 5.5. Rapid Lateral Flow Immunoassays
    • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Molecular / NAAT-based Kits
    • 5.6.1. Molecular / NAAT-based Kits Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Multiplex Panel Testing
    • 5.7.1. Multiplex Panel Testing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.8. Others
    • 5.8.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. At-home STI Testing Market: Sample Type Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. At-home STI Testing Market: Sample Type Movement Analysis
  • 6.3. At-home STI Testing Market by Sample Type Outlook (USD Million)
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 - 2033 for the following
  • 6.5. Blood
    • 6.5.1. Blood Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Urine
    • 6.6.1. Urine Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Oral Fluid/Saliva
    • 6.7.1. Oral Fluid/Saliva Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Vaginal Swab
    • 6.8.1. Vaginal Swab Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.9. Others
    • 6.9.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. At-home STI Testing Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. At-home STI Testing Market: Distribution Channel Movement Analysis
  • 7.3. At-home STI Testing Market by Distribution Channel Outlook (USD Million)
  • 7.4. Market Size & Forecasts and Trend Analyses, 2021 - 2033 for the following
  • 7.5. Online Pharmacies & D2C Platforms
    • 7.5.1. Online Pharmacies & D2C Platforms Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Retail Pharmacies
    • 7.6.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Public Health Distribution Programs
    • 7.7.1. Public Health Distribution Programs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Others
    • 7.8.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. At-home STI Testing Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Dashboard
  • 8.2. Market Size, & Forecasts Trend Analysis, 2021 - 2033:
  • 8.3. North America
    • 8.3.1. U.S.
      • 8.3.1.1. Key country dynamics
      • 8.3.1.2. Regulatory framework/ reimbursement structure
      • 8.3.1.3. Competitive scenario
      • 8.3.1.4. U.S. market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.3.2. Canada
      • 8.3.2.1. Key country dynamics
      • 8.3.2.2. Regulatory framework/ reimbursement structure
      • 8.3.2.3. Competitive scenario
      • 8.3.2.4. Canada market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.3.3. Mexico
      • 8.3.3.1. Key country dynamics
      • 8.3.3.2. Regulatory framework/ reimbursement structure
      • 8.3.3.3. Competitive scenario
      • 8.3.3.4. Mexico market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.4. Europe
    • 8.4.1. UK
      • 8.4.1.1. Key country dynamics
      • 8.4.1.2. Regulatory framework/ reimbursement structure
      • 8.4.1.3. Competitive scenario
      • 8.4.1.4. UK market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.4.2. Germany
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Regulatory framework/ reimbursement structure
      • 8.4.2.3. Competitive scenario
      • 8.4.2.4. Germany market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.4.3. France
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Regulatory framework/ reimbursement structure
      • 8.4.3.3. Competitive scenario
      • 8.4.3.4. France market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.4.4. Italy
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Regulatory framework/ reimbursement structure
      • 8.4.4.3. Competitive scenario
      • 8.4.4.4. Italy market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.4.5. Spain
      • 8.4.5.1. Key country dynamics
      • 8.4.5.2. Regulatory framework/ reimbursement structure
      • 8.4.5.3. Competitive scenario
      • 8.4.5.4. Spain market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.4.6. Norway
      • 8.4.6.1. Key country dynamics
      • 8.4.6.2. Regulatory framework/ reimbursement structure
      • 8.4.6.3. Competitive scenario
      • 8.4.6.4. Norway market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.4.7. Sweden
      • 8.4.7.1. Key country dynamics
      • 8.4.7.2. Regulatory framework/ reimbursement structure
      • 8.4.7.3. Competitive scenario
      • 8.4.7.4. Sweden market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.4.8. Denmark
      • 8.4.8.1. Key country dynamics
      • 8.4.8.2. Regulatory framework/ reimbursement structure
      • 8.4.8.3. Competitive scenario
      • 8.4.8.4. Denmark market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.5. Asia Pacific
    • 8.5.1. Japan
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. Japan market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.5.2. China
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. China market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.5.3. India
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. India market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.5.4. Australia
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework/ reimbursement structure
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Australia market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.5.5. South Korea
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Regulatory framework/ reimbursement structure
      • 8.5.5.3. Competitive scenario
      • 8.5.5.4. South Korea market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.5.6. Thailand
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Regulatory framework/ reimbursement structure
      • 8.5.6.3. Competitive scenario
      • 8.5.6.4. Thailand market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.6. Latin America
    • 8.6.1. Brazil
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Brazil market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.6.2. Argentina
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Argentina market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.7. MEA
    • 8.7.1. South Africa
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. South Africa market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.7.2. Saudi Arabia
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Saudi Arabia market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.7.3. UAE
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. UAE market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.7.4. Kuwait
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Kuwait market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
  • 9.2. Recent Developments & Impact Analysis by Key Market Participants
  • 9.3. Company Market Share Analysis, 2025
  • 9.4. Key Company Profiles
    • 9.4.1. OraSure Technologies Inc.
      • 9.4.1.1. Company overview
      • 9.4.1.2. Financial performance
      • 9.4.1.3. Product benchmarking
      • 9.4.1.4. Strategic initiatives
    • 9.4.2. Abbott
      • 9.4.2.1. Company overview
      • 9.4.2.2. Financial performance
      • 9.4.2.3. Product benchmarking
      • 9.4.2.4. Strategic initiatives
    • 9.4.3. bioLytical Laboratories Inc.
      • 9.4.3.1. Company overview
      • 9.4.3.2. Financial performance
      • 9.4.3.3. Product benchmarking
      • 9.4.3.4. Strategic initiatives
    • 9.4.4. Chembio Diagnostics, Inc.
      • 9.4.4.1. Company overview
      • 9.4.4.2. Financial performance
      • 9.4.4.3. Product benchmarking
      • 9.4.4.4. Strategic initiatives
    • 9.4.5. BD (Becton Dickinson)
      • 9.4.5.1. Company overview
      • 9.4.5.2. Financial performance
      • 9.4.5.3. Product benchmarking
      • 9.4.5.4. Strategic initiatives
    • 9.4.6. LetsGetChecked
      • 9.4.6.1. Company overview
      • 9.4.6.2. Financial performance
      • 9.4.6.3. Product benchmarking
      • 9.4.6.4. Strategic initiatives
    • 9.4.7. Everlywell
      • 9.4.7.1. Company overview
      • 9.4.7.2. Financial performance
      • 9.4.7.3. Product benchmarking
      • 9.4.7.4. Strategic initiatives
    • 9.4.8. NURX Inc.
      • 9.4.8.1. Company overview
      • 9.4.8.2. Financial performance
      • 9.4.8.3. Product benchmarking
      • 9.4.8.4. Strategic initiatives
    • 9.4.9. Hologic, Inc.
      • 9.4.9.1. Company overview
      • 9.4.9.2. Financial performance
      • 9.4.9.3. Product benchmarking
      • 9.4.9.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global at-home STI testing market, by infection, 2021 - 2033 (USD Million)
  • Table 4 Global at-home STI testing market, by test type, 2021 - 2033 (USD Million)
  • Table 5 Global at-home STI testing market, by sample type, 2021 - 2033 (USD Million)
  • Table 6 Global at-home STI testing market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 7 North America At-home STI Testing market, by region, 2021 - 2033 (USD Million)
  • Table 8 North America at-home STI testing market, by infection, 2021 - 2033 (USD Million)
  • Table 9 North America at-home STI testing market, by test type, 2021 - 2033 (USD Million)
  • Table 10 North America at-home STI testing market, by sample type, 2021 - 2033 (USD Million)
  • Table 11 North America at-home STI testing market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 12 U.S. at-home STI testing market, by infection, 2021 - 2033 (USD Million)
  • Table 13 U.S. at-home STI testing market, by test type, 2021 - 2033 (USD Million)
  • Table 14 U.S. at-home STI testing market, by sample type, 2021 - 2033 (USD Million)
  • Table 15 U.S. at-home STI testing market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 16 Canada at-home STI testing market, by infection, 2021 - 2033 (USD Million)
  • Table 17 Canada at-home STI testing market, by test type, 2021 - 2033 (USD Million)
  • Table 18 Canada at-home STI testing market, by sample type, 2021 - 2033 (USD Million)
  • Table 19 Canada at-home STI testing market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 20 Mexico at-home STI testing market, by infection, 2021 - 2033 (USD Million)
  • Table 21 Mexico at-home STI testing market, by test type, 2021 - 2033 (USD Million)
  • Table 22 Mexico at-home STI testing market, by sample type, 2021 - 2033 (USD Million)
  • Table 23 Mexico at-home STI testing market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 24 Europe at-home STI testing market, by country, 2021 - 2033 (USD Million)
  • Table 25 Europe at-home STI testing market, by infection, 2021 - 2033 (USD Million)
  • Table 26 Europe at-home STI testing market, by test type, 2021 - 2033 (USD Million)
  • Table 27 Europe at-home STI testing market, by sample type, 2021 - 2033 (USD Million)
  • Table 28 Europe at-home STI testing market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 29 UK at-home STI testing market, by infection, 2021 - 2033 (USD Million)
  • Table 30 UK at-home STI testing market, by test type, 2021 - 2033 (USD Million)
  • Table 31 UK at-home STI testing market, by sample type, 2021 - 2033 (USD Million)
  • Table 32 UK at-home STI testing market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 33 Germany at-home STI testing market, by infection, 2021 - 2033 (USD Million)
  • Table 34 Germany at-home STI testing market, by test type, 2021 - 2033 (USD Million)
  • Table 35 Germany at-home STI testing market, by sample type 2021 - 2033 (USD Million)
  • Table 36 Germany at-home STI testing market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 37 France at-home STI testing market, by infection, 2021 - 2033 (USD Million)
  • Table 38 France at-home STI testing market, by test type, 2021 - 2033 (USD Million)
  • Table 39 France at-home STI testing market, by sample type 2021 - 2033 (USD Million)
  • Table 40 France at-home STI testing market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 41 Italy at-home STI testing market, by infection, 2021 - 2033 (USD Million)
  • Table 42 Italy at-home STI testing market, by test type, 2021 - 2033 (USD Million)
  • Table 43 Italy at-home STI testing market, by sample type, 2021 - 2033 (USD Million)
  • Table 44 Italy at-home STI testing market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 45 Spain at-home STI testing market, by infection, 2021 - 2033 (USD Million)
  • Table 46 Spain at-home STI testing market, by test type, 2021 - 2033 (USD Million)
  • Table 47 Spain at-home STI testing market, by sample type, 2021 - 2033 (USD Million)
  • Table 48 Spain at-home STI testing market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 49 Denmark at-home STI testing market, by infection, 2021 - 2033 (USD Million)
  • Table 50 Denmark at-home STI testing market, by test type, 2021 - 2033 (USD Million)
  • Table 51 Denmark at-home STI testing market, by sample type 2021 - 2033 (USD Million)
  • Table 52 Denmark at-home STI testing market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 53 Sweden at-home STI testing market, by infection, 2021 - 2033 (USD Million)
  • Table 54 Sweden at-home STI testing market, by test type, 2021 - 2033 (USD Million)
  • Table 55 Sweden at-home STI testing market, by sample type, 2021 - 2033 (USD Million)
  • Table 56 Sweden at-home STI testing market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 57 Norway at-home STI testing market, by infection, 2021 - 2033 (USD Million)
  • Table 58 Norway at-home STI testing market, by test type, 2021 - 2033 (USD Million)
  • Table 59 Norway at-home STI testing market, by sample type, 2021 - 2033 (USD Million)
  • Table 60 Norway at-home STI testing market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 61 Asia Pacific at-home STI testing market, by country, 2021 - 2033 (USD Million)
  • Table 62 Asia Pacific at-home STI testing market, by infection, 2021 - 2033 (USD Million)
  • Table 63 Asia Pacific at-home STI testing market, by test type, 2021 - 2033 (USD Million)
  • Table 64 Asia Pacific at-home STI testing market, by sample type, 2021 - 2033 (USD Million)
  • Table 65 Asia Pacific at-home STI testing market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 66 Japan at-home STI testing market, by infection, 2021 - 2033 (USD Million)
  • Table 67 Japan at-home STI testing market, by test type, 2021 - 2033 (USD Million)
  • Table 68 Japan at-home STI testing market, by sample type, 2021 - 2033 (USD Million)
  • Table 69 Japan at-home STI testing market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 70 China at-home STI testing market, by infection, 2021 - 2033 (USD Million)
  • Table 71 China at-home STI testing market, by test type 2021 - 2033 (USD Million)
  • Table 72 China at-home STI testing market, by sample type 2021 - 2033 (USD Million)
  • Table 73 China at-home STI testing market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 74 India at-home STI testing market, by infection, 2021 - 2033 (USD Million)
  • Table 75 India at-home STI testing market, by test type, 2021 - 2033 (USD Million)
  • Table 76 India at-home STI testing market, by sample type, 2021 - 2033 (USD Million)
  • Table 77 India at-home STI testing market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 78 Australia at-home STI testing market, by infection, 2021 - 2033 (USD Million)
  • Table 79 Australia at-home STI testing market, by test type, 2021 - 2033 (USD Million)
  • Table 80 Australia at-home STI testing market, by sample type, 2021 - 2033 (USD Million)
  • Table 81 Australia at-home STI testing market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 82 South Korea at-home STI testing market, by infection, 2021 - 2033 (USD Million)
  • Table 83 South Korea at-home STI testing market, by test type, 2021 - 2033 (USD Million)
  • Table 84 South Korea at-home STI testing market, by sample type, 2021 - 2033 (USD Million)
  • Table 85 South Korea at-home STI testing market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 86 Thailand at-home STI testing market, by infection, 2021 - 2033 (USD Million)
  • Table 87 Thailand at-home STI testing market, by test type, 2021 - 2033 (USD Million)
  • Table 88 Thailand at-home STI testing market, by sample type, 2021 - 2033 (USD Million)
  • Table 89 Thailand at-home STI testing market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 90 Latin America at-home STI testing market, by country, 2021 - 2033 (USD Million)
  • Table 91 Latin America at-home STI testing market, by infection, 2021 - 2033 (USD Million)
  • Table 92 Latin America at-home STI testing market, by test type, 2021 - 2033 (USD Million)
  • Table 93 Latin America at-home STI testing market, by sample type, 2021 - 2033 (USD Million)
  • Table 94 Latin America at-home STI testing market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 95 Brazil at-home STI testing market, by infection, 2021 - 2033 (USD Million)
  • Table 96 Brazil at-home STI testing market, by test type, 2021 - 2033 (USD Million)
  • Table 97 Brazil at-home STI testing market, by sample type, 2021 - 2033 (USD Million)
  • Table 98 Brazil at-home STI testing market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 99 Argentina at-home STI testing market, by infection, 2021 - 2033 (USD Million)
  • Table 100 Argentina at-home STI testing market, by test type, 2021 - 2033 (USD Million)
  • Table 101 Argentina at-home STI testing market, by sample type, 2021 - 2033 (USD Million)
  • Table 102 Argentina at-home STI testing market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 103 Middle East & Africa at-home STI testing market, by country, 2021 - 2033 (USD Million)
  • Table 104 Middle East & Africa at-home STI testing market, by infection, 2021 - 2033 (USD Million)
  • Table 105 Middle East & Africa at-home STI testing market, by test type, 2021 - 2033 (USD Million)
  • Table 106 Middle East & Africa at-home STI testing market, by sample type, 2021 - 2033 (USD Million)
  • Table 107 Middle East & Africa at-home STI testing market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 108 South Africa at-home STI testing market, by infection, 2021 - 2033 (USD Million)
  • Table 109 South Africa at-home STI testing market, by test type, 2021 - 2033 (USD Million)
  • Table 110 South Africa at-home STI testing market, by sample type, 2021 - 2033 (USD Million)
  • Table 111 South Africa at-home STI testing market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 112 Saudi Arabia at-home STI testing market, by infection, 2021 - 2033 (USD Million)
  • Table 113 Saudi Arabia at-home STI testing market, by test type, 2021 - 2033 (USD Million)
  • Table 114 Saudi Arabia at-home STI testing market, by sample type, 2021 - 2033 (USD Million)
  • Table 115 Saudi Arabia at-home STI testing market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 116 UAE at-home STI testing market, by infection, 2021 - 2033 (USD Million)
  • Table 117 UAE at-home STI testing market, by test type, 2021 - 2033 (USD Million)
  • Table 118 UAE at-home STI testing market, by sample type, 2021 - 2033 (USD Million)
  • Table 119 UAE at-home STI testing market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 120 Kuwait at-home STI testing market, by infection, 2021 - 2033 (USD Million)
  • Table 121 Kuwait at-home STI testing market, by test type, 2021 - 2033 (USD Million)
  • Table 122 Kuwait at-home STI testing market, by sample type, 2021 - 2033 (USD Million)
  • Table 123 Kuwait at-home STI testing market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Information procurement
  • Fig. 2 Primary research pattern
  • Fig. 3 Market research approaches
  • Fig. 4 Value chain-based sizing & forecasting
  • Fig. 5 Market formulation & validation
  • Fig. 6 At-home STI Testing market segmentation
  • Fig. 7 Market driver analysis (current & future impact)
  • Fig. 8 Market restraint analysis (current & future impact)
  • Fig. 9 SWOT analysis, by factor (political & legal, economic, and technological)
  • Fig. 10 Porter's five forces analysis
  • Fig. 11 At-home STI testing market, infection outlook key takeaways, 2025 & 2033 (USD Million)
  • Fig. 12 At-home STI testing market, infection movement analysis, 2025 & 2033 (USD Million)
  • Fig. 13 HIV market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 14 Chlamydia (CT) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 15 Gonorrhea (NG) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 16 Syphilis market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 17 Trichomoniasis market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 18 HPV market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 19 Hepatitis B & C market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 20 Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 21 At-home STI testing market, test type outlook key takeaways, 2025 & 2033 (USD Million)
  • Fig. 22 At-home STI testing market, test type movement analysis, 2025 & 2033 (USD Million)
  • Fig. 23 Rapid lateral flow immunoassays market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Molecular / NAAT-based Kits market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Multiplex panel testing market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 At-home STI testing market, sample type outlook key takeaways, 2025 & 2033 (USD Million)
  • Fig. 28 At-home STI testing market, sample type movement analysis, 2025 & 2033 (USD Million)
  • Fig. 29 Blood market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 Urine market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 Oral fluid/Saliva market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Vaginal swab market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 At-home STI testing market, distribution channel outlook key takeaways, 2025 & 2033 (USD Million)
  • Fig. 35 At-home STI testing market, distribution channel movement analysis, 2025 & 2033 (USD Million)
  • Fig. 36 Online pharmacies & D2C platforms market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Retail pharmacies market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Public health distribution programs market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 North America at-home STI testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 US at-home STI testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Canada at-home STI testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 Mexico at-home STI testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Europe at-home STI testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 UK at-home STI testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Germany at-home STI testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 France at-home STI testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Spain at-home STI testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Italy at-home STI testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Denmark at-home STI testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Sweden at-home STI testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Norway at-home STI testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Asia Pacific at-home STI testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 China at-home STI testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Japan at-home STI testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 56 India at-home STI testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 South Korea at-home STI testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 58 Australia at-home STI testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Thailand at-home STI testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 Latin America at-home STI testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Brazil at-home STI testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 62 Argentina at-home STI testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 Middle East and Africa at-home STI testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 South Africa at-home STI testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 65 Saudi Arabia at-home STI testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 66 UAE at-home STI testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 67 Kuwait at-home STI testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 List of key emerging companies